A phase I clinical trial of the CHP-MAGE-A4 vaccine containing 300 μg MAGE-A4 elicited CD8 T-cell and humoral responses when administered subcutaneously in patients with advanced esophageal, stomach, or lung cancer [230]. This evidence concerns the gene MAGEA4 and lung cancer.